HIGHLIGHTS

4169 Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

4171 PD-1 Blockade in Chinese versus Western Patients with Melanoma
   Alexander N. Shoushtari, Riyue Bao, and Jason J. Luke
   See related article, p. 4250

4174 Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML
   Joshua F. Zeidner
   See related article, p. 4280

4177 TCR Repertoire Changes during TIL Expansion: Clonal Selection or Drifting?
   Maria Lozano-Rabella and Alena Gros
   See related article, p. 4289

CCR Drug Updates

4180 FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer
   Suparna Wedam, Lola Fashoyin-Aje, Xin Gao, Erik Bloomquist, Shenghui Tang, Rajeshwari Sridhara, Kirsten B. Goldberg, Bellinda L. King-Kallimanis, Marc R. Theoret, Amna Ibrahim, Laleh Amiri-Kordestani, Richard Pazdur, and Julia A. Beaver

Review

4186 PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice
   Iñaki Eguren-Santamaría, Miguel F. Sanmamed, Sarah B. Goldberg, Harriet M. Kluger, Miguel A. Idoate, Benjamin Y. Lu, Jesús Corral, Kurt A. Schalper, Roy S. Herbst, and Ignacio Gil-Bazo

Perspectives

4198 The World of Clinical Trial Development Post COVID-19: Lessons Learned from a Global Pandemic
   Fatima Karzai, Ravi A. Madan, and William I. Dahut

4201 Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era
   Michèle Maio, Omid Hamid, James Larkin, Alessia Covre, Maresa Altmont, Luana Calabrò, Santosh A. Vardhana, Caroline Robert, Ramy Ibrahim, Andrea Anichini, Jedd D. Wolchok, and Anna Maria Di Giacomo

CLINICAL TRIALS: TARGETED THERAPY

4206 EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
   Stephanie Lheureux, Ana Oaknin, Swati Garg, Jeffrey P. Bruce, Ainhoa Madariaga, Neesha C. Dhani, Valerie Bowering, Justin White, Sarah Accardi, Qian Tan, Marsela Braunstein, Katherine Karakasis, Julia Cirlan, Stephanie Pedersen, Tianliam Li, Lorena Fariñas-Madrid, Yeh Chen Lee, Zhihui (Amy) Liu, Trevor J. Pugh, and Amit M. Oza

4216 Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton’s Tyrosine Kinase
   Yuqin Song, Keshu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Hualai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Haiyi Guo, Lei Zhou, Rebecca Elstrom, Jane Huang, William Novotny, Rachel Wei, and Jun Zhu

4225 A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma
TABLE OF CONTENTS

4233

NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response
Sandra M. Swain, Gong Tang, Heather Ann Brauer, David S. Goerlitz, Peter C. Lucas, André Robidoux, Brent T. Harris, Hanna Bandos, Yuqi Ren, Charles E. Geyer Jr, Priya Rastogi, Eleftherios P. Mamounas, and Norman Wolmark

CLINICAL TRIALS: IMMUNOTHERAPY

4242

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+/HER2− Primary Breast Cancer

4250

Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial
Bixia Tang, Zhuhong Chi, Yingbo Chen, Xiufeng Liu, Di Wu, Jing Chen, Xin Song, Weifeng Wang, Lihou Dong, Hai Feng Song, Hai Wu, Hui Feng, Sheng Yao, Shuikui Qin, Xiaoshi Zhang, and Jun Guo
See related commentary, p. 4171

4260

Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
See related commentary, p. 4171

4268

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

4280

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis
See related commentary, p. 4174

4289

The Outcome of Ex Vivo TIL Expansion is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones
See related commentary, p. 4177

4302

High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma
Wen Sun, Shi-Chao Li, Li Xu, Wei Zhong, Zhen-Guang Wang, Chu-zhi Pan, Jing Li, Guang-Zhi Jin, Na Ta, Wei Dong, Dan Liu, Hui Liu, Hong-Yang Wang, and Jin Ding

4313

The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer
Sarah M. McCuaig, David Barras, Elizabeth H. Mann, Matthias Friedrich, Samuel J. Bullers, Alina Janney, Lucy C. Garner, Enric Domingo, Viktor Hendrik Koelzer, Mauro Delorenzi, Sabine Tejpar, Timothy S. Maughan, Nathaniel R. West, and Fiona Powrie

4326

Prognostic Significance of Immune Cell Populations Identified by Machine Learning in Colorectal Cancer Using Routine Hematoxylin and Eosin–Stained Sections

Downloaded from clincancerres.aacrjournals.org on October 17, 2021. © 2020 American Association for Cancer Research.
Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non-Small Cell Lung Cancer

AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer

Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling
Jon Zugazagoitia, Swati Gupta, Yuting Liu, Kit Fuhrman, Scott Gettinger, Roy S. Herbst, Kurt A. Schalper, and David L. Rimm

Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas
Lindsay Scheetz, Padma Kadiyala, Xiaoqi Sun, Sejin Son, Alireza Hassan Najafabadi, Marisa Aikins, Pedro R. Lowenstein, Anna Schwendeman, Maria G. Castro, and James J. Moon

Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules
Maxime Meylan, Florent Petitprez, Laetitia Lacroix, Luca Di Tommaso, Massimo Roncalli, Antoine Bougouin, Alexis Laurent, Giuliana Amaddeo, Daniele Sommacale, Hélène Regnault, Jonathan Derman, Cécile Charpy, Fouad Ladjil, Jean-Michel Pawlotsky, Catherine Sautès-Fridman, Wolf H. Fridman, and Julien Calderaro

CD8+ T-cell–Mediated Immunoeediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas
Joshua R. Kane, Junfei Zhao, Takashi Tsuruuchi, Brice Laffleur, Victor A. Arrieta, Aayushi Mahajan, Ganesh Rao, Angeliki Mela, Crismita Dmelo, Li Chen, Daniel Y. Zhang, Edgar Gonzalez-Buendia, Catalina Lee-Chang, Ting Xiao, Gerson Rothschild, Utiya Basu, Craig Horbinski, Maciej S. Lesniak, Amy B. Heimberger, Raul Rabadán, Peter Canoll, and Adam M. Sonabend

Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
Jennifer X. Ji, Dawn R. Cochrane, Basile Tessier-Cloutier, Shary Yutin Chen, Germain Ho, Khyatiben V. Pathak, Isabel N. Alcazar, David Farnell, Samuel Leung, Angela Cheng, Christine Chow, Shane Colborne, Gian Luca Negri, Friedrich Kommoss, Anthony Karnezis, Gregg B. Morin, Jessica N. McAlpine, C. Blake Gilks, Bernard E. Weissman, Jeffrey M. Trent, Lynn Hoang, Patrick Pirrotte, Yemin Wang, and David G. Huntsman

Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition
Lucas Basler, Hubert S. Gabryś, Sabrina A. Hogan, Matea Pavic, Marta Bogowicz, Diem Vuong, Stephanie Tanadini-Lang, Robert Förster, Ken Kudura, Martin W. Huellner, Reinhard Dummer, Matthias Guckenberger, and Mitchell P. Levesque
ABOUT THE COVER

The cover shows multiplex immunofluorescence staining of a human NSCLC case (cytokeratin in green, CD3 in red, and CD56 in white). There is abundant CD56 expression in the stroma, including CD56+/CD3− cells (NK cells) and CD56+/CD3− cells (NKT cells). For details, see the article by Zugazagoitia and colleagues on page 4360 of this issue.
Clinical Cancer Research

26 (16)

Clin Cancer Res 2020;26:4169-4425.

Updated version  Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/26/16

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/26/16. Click on "Request Permissions" which will take you to the Copyright Clearance Center’s (CCC) Rightslink site.